Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marie-Paule Sablin

Showing results (21-30 of 51) with videos related to

Pageof 6
Sort By:
Drugs in R&D|September 25, 2021
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with ImmunotherapyPauline Vaflard, Xavier Paoletti, Vincent Servois, et al.
Plos One|July 9, 2016
Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2021
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutationAnne Patsouris, Kadija Diop, Olivier Tredan, et al.
JCO Precision Oncology|January 7, 2022
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Grégoire Marret, Ivan Bièche, Célia Dupain, et al.
Oncogene|February 27, 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysisAntoine Vasseur, Luc Cabel, Caroline Hego, et al.
Clinical Chemistry|January 12, 2017
Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast CancerFrancesca Riva, Francois-Clement Bidard, Alexandre Houy, et al.
Lung Cancer (Amsterdam, Netherlands)|July 13, 2023
Accelerated subsequent lung cancer after post-operative radiotherapy for breast cancerClémence Basse, Julien Ancel, Marie-Ange Massiani, et al.
Therapeutic Advances in Medical Oncology|July 2, 2025
Clinical landscape for patients with head and neck cancers enrolled in phase I trials at a tertiary referral centerDaria Maria Filippini, Raphael Sanchez, Etienne Bastien, et al.
Breast Cancer Research : BCR|November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trialWilliam Jacot, Paul Cottu, Frederique Berger, et al.
Oncotarget|June 23, 2016
Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomasMarie-Paule Sablin, Coraline Dubot, Jerzy Klijanienko, et al.
Pageof 6

Showing results (21-30 of 51) with videos related to

Sort By:
Pageof 6
Drugs in R&D|September 25, 2021
Dissociated Responses in Patients with Metastatic Solid Tumors Treated with ImmunotherapyPauline Vaflard, Xavier Paoletti, Vincent Servois, et al.
Plos One|July 9, 2016
Correction: Beyond Axillary Lymph Node Metastasis, BMI and Menopausal Status Are Prognostic Determinants for Triple-Negative Breast Cancer Treated by Neoadjuvant ChemotherapyHélène Bonsang-Kitzis, Léonor Chaltier, Lisa Belin, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2021
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutationAnne Patsouris, Kadija Diop, Olivier Tredan, et al.
JCO Precision Oncology|January 7, 2022
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT)Grégoire Marret, Ivan Bièche, Célia Dupain, et al.
Oncogene|February 27, 2024
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysisAntoine Vasseur, Luc Cabel, Caroline Hego, et al.
Clinical Chemistry|January 12, 2017
Patient-Specific Circulating Tumor DNA Detection during Neoadjuvant Chemotherapy in Triple-Negative Breast CancerFrancesca Riva, Francois-Clement Bidard, Alexandre Houy, et al.
Lung Cancer (Amsterdam, Netherlands)|July 13, 2023
Accelerated subsequent lung cancer after post-operative radiotherapy for breast cancerClémence Basse, Julien Ancel, Marie-Ange Massiani, et al.
Therapeutic Advances in Medical Oncology|July 2, 2025
Clinical landscape for patients with head and neck cancers enrolled in phase I trials at a tertiary referral centerDaria Maria Filippini, Raphael Sanchez, Etienne Bastien, et al.
Breast Cancer Research : BCR|November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trialWilliam Jacot, Paul Cottu, Frederique Berger, et al.
Oncotarget|June 23, 2016
Identification of new candidate therapeutic target genes in head and neck squamous cell carcinomasMarie-Paule Sablin, Coraline Dubot, Jerzy Klijanienko, et al.
Pageof 6